



PCT/03/01527

REC'D 09 DEC 2003

WIPO

PCT

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**Patent Office  
Canberra**

I, JANENE PEISKER, TEAM LEADER EXAMINATION SUPPORT AND  
SALES hereby certify that annexed is a true copy of the Provisional specification  
in connection with Application No. 2002952682 for a patent by QUEENSLAND  
UNIVERSITY OF TECHNOLOGY as filed on 14 November 2002.



WITNESS my hand this  
Twenty-seventh day of November 2003

A handwritten signature in black ink, appearing to read 'J. Peisker'.

**JANENE PEISKER  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES**

**BEST AVAILABLE COPY**

AUSTRALIA

---

*Patents Act 1990*

---

## **PROVISIONAL SPECIFICATION**

**Invention Title: "A METHOD OR APPARATUS FOR  
INHIBITING MYOPIA DEVELOPMENT  
IN HUMANS"**

**The invention is described in the following statement:**

## TITLE:

**"A METHOD OR APPARATUS FOR INHIBITING MYOPIA  
DEVELOPMENT IN HUMANS"**

**FIELD OF THE INVENTION**

5                   This invention relates to a method or apparatus for inhibiting  
the development of myopia in humans.

**BACKGROUND OF THE INVENTION**

Myopia is a refractive eye disorder that effects a large segment  
of the population (30% in Australia, up to 90% in Asia). In particular it is  
10           characterised by a normal ability to see nearby objects but a reduced ability  
to see objects at a far distance. Thus the colloquial term for this condition is  
nearsightedness.

                  This condition is known to onset during childhood, especially  
from the ages of 6 to 14, and to worsen as a person grows through  
15           adulthood. The person's vision becomes increasingly blurry when focusing  
on distant objects, requiring increasingly stronger remedial correction over  
time.

                  There are various explanations for the presence of myopia  
including the physiology of the eye, where the eyeball has developed with a  
20           longer than normal length, possibly due to developing an enlarged vitreous  
chamber, alternately the cornea or the lens may be too strongly powered.

                  These developments result in the eye not needing to  
accommodate to focus on near objects and creating a blurry image on the  
retina when focusing on more distant objects. Further it is suggested that

both genetic and environmental factors are important in myopia development with prolonged near work being associated with myopia.

In "Experimental Myopia in Cats Reared in Strobic Illumination" (Cremieux, Orban, Duysen, Amblard and Kennedy), experiments on cats  
5 have shown that myopia can be induced by subjecting kittens to low frequency strobing lights (~2Hz) for more than 4 hours per day. This suggests that test subject animals can be prepared for myopia studies by exposing young animals to low frequency strobic illumination while they are developing their eyesight.

10 A popular way to compensate for myopia is to use concave lenses, for example in eyeglasses or contact lenses. The concave lens shifts the image plane to be coincident with the retina and thus brings the distant objects into clearer focus. A problem with these lenses is that as the eye continues to elongate, stronger and stronger lenses are required and vision  
15 gradually worsens.

Another form of correcting myopia is to operate on the eye lenses using refractive laser surgery techniques. This remedy is expensive and the long term effects are not yet known. Furthermore this treatment is only available on adults with stabilised myopic eyes and requires further  
20 operations to adjust continuing failing eyesight throughout a lifetime. Correction of the myopia can also result in a slight reduction in best vision.

Another costly remedy is for the subject to take drugs and eye drops (for example pirenzepine) to combat the myopia although there are not currently any drops that are known to effectively inhibit myopia development.

Once again, the long term effects of these remedies are unknown and it is a costly solution to the problem involving continual prescriptions and health risks. Further, the eye drops may include side effects of dilating the pupil and reducing the focusing ability of the subject.

- 5                    There is a need for a low cost, non-invasive treatment that assists in the retardation or inhibition of the development of myopia, especially one that is safe for use on children during the onset of myopia.

#### OBJECT OF THE INVENTION

- 10                   It is an object of the invention to overcome or alleviate one or more of the above problems or to provide the consumer with a useful commercial choice.

#### DISCLOSURE OF THE INVENTION

- 15                   In one form, although it need not be the only or indeed the broadest form, the invention resides in a method of inhibiting myopia development in a human including the steps of:

                    prescribing a frequency and exposure time of a strobing or flickering light to reduce the rate of myopia development for the human;

                    treating the human with a strobing or flickering light at the prescribed frequency and exposure time each day.

- 20                   Preferably, the method includes the step of measuring the myopia of a subject.

                    In another form, the invention resides in a method of inhibiting myopia development in humans including the step of:

                    exposing the eyes of a subject to light flashing at a frequency in

the range of 1 to 60 Hz for at least twenty minutes per day each day or alternate days.

Preferably, the method includes a feedback loop for adjusting the treatment in response to the subject's measured progress.

5                    Preferably, the method will be operated for frequencies between 5 and 20 Hz.

Preferably the method will include treatment being applied for 5 minute periods every hour over a 6 to 10 hour period of each day.

Preferably, the treatment will be applied during daylight hours.

10                    In another form, the invention resides in an apparatus for inhibiting myopia developments in humans comprising:

a strobable light;

a means of adjusting a frequency at which the light strobes;

a means of adjusting a period of time over which the light

15                    strobes;

wherein said light strobes at a desired frequency for a desired time period.

The apparatus may further comprise:

20                    a feedback means of measuring myopia and making an adjustment to the period of time and the frequency the light strobes in response to the measured myopia;

Suitably, the apparatus operates at a frequency in the range 1 to 60 Hz.

Most preferably, the frequency used is in the range 5 to 20 Hz.

Generally the frequency used will compensate for the frequency of the background lighting.

Suitably, the time period will last for at least twenty minutes each day.

5 Most preferably the treatment will be applied for 10 minute periods every hour over a 6 to 10 hour period.

Generally the intensity of the light used will compensate for the intensity of the background lighting.

10 Preferably, the wavelength of the light will be in the visible range.

Most preferably, the wavelength of the light will be about 550 nm.

The method will preferably involve visible light (excluding ultraviolet and infrared) and may exclude short wavelengths (blue light).

15 Suitably the wavelength of light will be adapted to compensate for the wavelength of the background light.

Preferably, the apparatus may further include a base.

Preferably the base will be in the form of eyeglass frames with the light located near the hinge.

20 In another form the base will be mountable to a table.

The base may further comprise a lamp stand.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention will now be described with reference to the accompanying drawings in which:

FIG. 1 shows a flow diagram of the steps involved in the invention;

FIG. 2 shows a diagram of the invention mounted to a eyeglass base;

5                   FIG. 3 shows a diagram of the invention mounted to a lamp stand base.

#### DETAILED DESCRIPTION OF THE DRAWINGS

The first step in treating myopia is to assess the subject for their current condition. There are various means for testing myopia including  
10    using an ophthalmoscope, refractometer, infrared retinoscopy, A-scan ultrasound, or flicker ERG, to test the reflection from the retina, with myopia being diagnosed when the subject's refraction is measured to be in the range of 0D to - 10 D, with more negative values representing more severe myopia. Once the subject is identified as myopic, the extent of myopia can  
15    be assessed to determine the best treatment.

A more simple and transportable method of measuring myopia can be obtained by using thin filaments measuring flicker ERG. It is understood that this would allow measurements to be made in background lighting conditions so specific environments could be accurately  
20    compensated by the treatment.

Once the extent of myopia is known, the next step is to determine a specific treatment for the subject. In particular, specific frequency ranges and durations for treatment will target the particular myopia. Stronger cases may require higher frequencies and longer duration



of treatment.

Factors such as background lighting frequency, background lighting wavelength and background lighting intensity will need to be compensated by the strobe light for the best results. In particular, if background lighting is incandescent it does not flicker and provides light with a wavelength in the yellow range around 600 nm, while halogen lighting oscillates around 50Hz with light wavelengths in the blue region around 410 to 430 nm.

White light stimulates the maximum number of cone photoreceptors in the eye, as it activates the red, green and blue cones equally. Hence the method or apparatus will be most effective for stimulating improved vision when the subject is exposed to white light. Thus when the background lighting is blue, as in halogen lighting, the applied lighting must compensate for the lack of red and green wavelengths. Alternatively, when the background lighting is yellow, as in incandescent lighting, the compensating light must be more in the blue green bandwidth range.

Intensity of the background lighting will also need to be considered when prescribing a strobe light. The optimal intensity for treatment is 1000 to 1300 lumen. Thus if the background lighting is dimmer than this, the treatment will not work effectively as the strobing light will be distracting and visually disturbing. When the background lighting is at the high end of this intensity range, the strobe light can be brightened to complement it.

Additionally the frequency of the strobe light will need to be

calculated to compensate for the background lighting frequency, for example, the 50 Hz of halogen lighting or the lack of flicker in incandescent lighting. A typical frequency for the device would be within the range 5 to 20HZ, but it would be possible to use frequencies between 1 to 60Hz to the same effect.

- 5 The impact of strobe light on subjects would need to be considered before prescribing the treatment, as it is understood epilepsy can be triggered by certain frequencies and thus the treatment would not be useful for a subject with epileptic tendencies.

- 10 After characterising the myopia and calculating the treatment parameters, the next step is to prescribe a device for the subject to use for treatment. For example a light emitting diode (LED) could be positioned on a base worn on the subject's head during reading. The diode would emit light at a particular wavelength, with a programmed frequency, programmed illumination/dimness and programmed duration determined specifically for the subject.
- 15

The light emitting diode device would include means for adjusting the frequency, illumination and duration of treatment as required for the subject. The diodes are replaceable to provide for different wavelengths of light for treatment as required.

- 20 Another embodiment would be to use a strobe light such as a Xenon lamp on a base to emit the light for treatment. Once again, this lamp would need to include a means for adjusting the frequency, illumination and duration of the light to be used on treating subjects.

The base as illustrated in FIG. 2 and FIG. 3 could comprise a

portable structure such as spectacle frames (20) or other head attachments to allow the light, such as a LED (21), to be positioned close to the eye and controlled by a microprocessor (22). Additionally the base could be a more solid structure, such as a lamp base (30), formed to rest on a desk or table during use. In this form the light source would be a Xenon strobe lamp (31) supported on the base (30) and having a control to adjust the frequency (33), on/off toggle switch (34) and an adjustable timer (35).

The optimal delivery of the strobe treatment would be for 10 minutes per hour throughout the day. In practical application, it may also be provided in a single duration once per day. For children at school, an effective treatment would be during an hour of reading after school and before sunset, for maximum light intensity.

The final step in the iterative process is a feedback loop, where myopia is remeasured and treatment is recalculated. The success of the treatment will be measurable as a reduction in the myopia of the subject. As the myopia reduces the treatment required will need to be adjusted with frequencies reduced and duration decreased. This would be achieved by adjusting the adjustment means for the frequency and the duration.

A professional with the measurement methods described for diagnosing the myopia can perform the measurement of the myopia, at a designated time after treatments. Additionally a feedback mechanism can be included with the device, which automatically adjusts the treatment. Once the reduced myopia is measured, a new program of treatment will be calculated considering new frequency and new duration required.

A feedback mechanism for automatically adjusting the treatment would measure the electrical signals from the retinal output and calculate the new required parameters, or a subjective psychophysical equivalent could be used.

5 Treatment of subjects will be measured as a reduction in the rate of growth of myopia with an expected reduction of 50%. This treatment is an iterative process with the measurements providing a feedback mechanism so the treatment can be controlled as required. At a predetermined point of measured myopia progression, such as -0.25 D,  
10 treatment may no longer be needed and the subject should be monitored for future regression in vision.

Recent scientific experiments on animals have suggested that exposing the eyes of test subjects to flashing lights at a certain frequencies can cause myopia to develop. This has been useful in providing animal  
15 subjects with myopia so that various remedies can be tested on them. This research is in conflict with the invention herein described, as flashing lights are being used to treat existing myopia rather than cause it.

As domestic lighting is commercially available in specific packaged forms, specific compensating lights can be prepared for use with  
20 lighting available in the market. For example if the background light is an incandescent 100W globe, the compensating frequency, wavelength and luminosity can be predetermined.

It should be appreciated that various other changes and modifications may be made to the embodiments described without departing

from the spirit or scope of the invention.

DATED this Fourteenth day of November 2002.


5

QUEENSLAND UNIVERSITY OF TECHNOLOGY

By its Patent Attorneys

FISHER ADAMS KELLY

10



**FIG 1**




FIG 2




FIG 3

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**